Italiano
English2022
9M
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards
The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests and internationally active in the Life Science sector, today examined and approved the consolidated economic and financial results of the first 9 months of 2022.
H1
Strong revenues growth in the First Half of 2022
Saluggia (Italy), August 3, 2022 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests and internationally active in the Life Science sector, today examined and approved the Half-Year Financial Report at June 30, 2022.
Highlights
€ 685 mln
REVENUES
€ 269 mln
Adjusted EBITDA
€ 169 mln
Adjusted Net Profit
Q1
Strong growth in revenues and cash flow generation in Q1 2022
Saluggia (Italy), May 6, 2022 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests and internationally active in the Life Science sector, meeting today examined and approved the consolidated economic and financial results for Q1 2022.
Highlights
€ 358 mln
REVENUES
€ 150 mln
Adjusted EBITDA
€ 96 mln
ADJUSTED NET PROFIT
€ 116 mln
FREE CASH FLOW
2021
FY
DiaSorin business momentum and the Luminex acquisition drive up revenues, net result and cash flow generation in 2021
Saluggia (Italy), March 16, 2022 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2021
Highlights
€ 1,237.7 mln
REVENUES
€ 543.1 mln
Adjusted EBITDA
€ 356.9 mln
ADJUSTED NET PROFIT
€ 300.7 mln
FREE CASH FLOW
9M
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021
Saluggia (Italy), November 11, 2021 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, reviewed and approved 9M 2021 consolidated economic and financial results.
Highlights (mln/€)
858.9
REVENUES
383.2
Adjusted EBITDA
229.3
NET PROFIT
223.7
FREE CASH FLOW
H1
DiaSorin: Revenues and Profitability continue upward momentum in H1 2021, with Guidance raised following the acquisition of Luminex
Saluggia (Italy), July 30, 2021 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), today examined and approved the Half-Year Financial Report at June 30, 2021
Highlights
€515.4 mln
REVENUES
€244.2 mln
Adjusted EBITDA
€150.0 mln
NET PROFIT
€436.3 mln
NET FINANCIAL POSITION
€125.8 mln
FREE CASH FLOW
+299 units
LIAISON XL PLACEMENTS
Q1
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021
Saluggia (Italy), May 14, 2021 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests, examined and approved the Q1’21 consolidated economic and financial results.
Highlights
€266.7 mln
REVENUES
€129.6 mln
Adjusted EBITDA
€78.2 mln
NET PROFIT
€393.6 mln
NET FINANCIAL POSITION
€79.7 mln
FREE CASH FLOW
+183 units
IMMUNODIAGNOSTIC INSTRUMENTS’ PLACEMENTS
2020
FY
DiaSorin – Revenues, Profitability and Cash Flow Generation hit record highs in 2020
Saluggia (Italy), March 11, 2021 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2020.
Highlights
€881.3 mln
REVENUES
€385.3 mln
EBITDA
€248.3 mln
NET PROFIT
€305.3
NET FINANCIAL POSITION
€232.2 mln
FREE CASH FLOW
+598 units
IMMUNODIAGNOSTIC INSTRUMENTS’ PLACEMENTS
9M
North America growth drives up revenues and profitability in the first 9 months of 2020, with strong business acceleration in the third Quarter
Saluggia (Italy), November 11, 2020 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, reviewed and approved 9M 2020 consolidated economic and financial results.
Numeri chiave
€ 610.1 mln
REVENUES
€ 257.7 mln
EBITDA
€ 162.5 mln
NET PROFIT
€ 256.1 mln
NET FINANCIAL POSITION
€ 152.5 mln
FREE CASH FLOW
+416 UNITS
LIAISON XL PLACEMENTS
H1
North America business growth drives Group revenues and profitability in the first half of 2020
Saluggia (Italy), July 30, 2020 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, reviewed and approved H1 2020 consolidated economic and financial results.
Highlights
€ 382.3 mln
REVENUES
€153.6 mln
EBITDA
€94.7 mln
NET PROFIT
€ 190.4 mln
NET FINANCIAL POSITION
€ 73.9 mln
FREE CASH FLOW
+ 241 units
INSTRUMENTS PLACEMENT
Q1
DiaSorin Group reports revenue growth and confirmed profitability in the first quarter 2020 despite the impact of the pandemic
Saluggia (Italy), May 13, 2020 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests, examined and approved the Q1’20 consolidated economic and financial results
Highlights
€ 174.6 mln
REVENUES
€ 64.5 mln
EBITDA
€ 37.7 mln
NET PROFIT
€ 215.5 mln
NET FINANCIAL POSITION
€ 39.8 mln
FREE CASH FLOW
+94 units
INSTRUMENTS PLACEMENTS
2019
FY
DiaSorin - Cash flow generation and net profit hit record highs in 2019
Saluggia (Italy), March 11, 2020 – The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the research, production and marketing of diagnostic tests, meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2019
Highlights
€706.3 mln
REVENUES
€276.8 mln
EBITDA
€175.7 mln
NET PROFIT
€172.9 mln
NET FINANCIAL POSITION
€180.1 mln
FREE CASH FLOW
+440 units
INSTRUMENTS PLACEMENTS
9M
Record free cash flow generation along with growth in revenues and profitability for DiaSorin in the first 9 months of 2019
Saluggia (Italy), November 6, 2019 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, met today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, and examined and approved 9M 2019 consolidated economic and financial results.
Highlights
€525.1 mln
REVENUES
€208.9 mln
EBITDA
€126.7 mln
NET PROFIT
+€132.8 mln
NET FINANCIAL POSITION
€138.3 mln
FREE CASH FLOW
+307 units
LIAISON/LIAISON XL INSTALLED
H1
DiaSorin Board of Directors approves first half 2019 results. Growth in revenues and profitability.
Saluggia (Italy), July 31, 2019 - The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), a global leader in the production of diagnostic tests, meeting today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, reviewed and approved H1 2019 consolidated economic and financial results.
Highlights
€350.3 mln
REVENUES
€139.3 mln
EBITDA
€84.0 mln
NET PROFIT
+€62.0 mln
NET FINANCIAL POSITION
€69.5 mln
FREE CASH FLOW
+212 units
LIAISON/LIAISON XL INSTALLED
Q1
DiaSorin Group reports growth in profitabilitity and strong free cash flow generation in the first quarter 2019
Saluggia (Italy), May 9, 2019 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, meeting today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, reviewed and approved Q1 2019 consolidated economic and financial results.
Highlights
€170.8 mln
REVENUES
€67.5 mln
EBITDA
€40.4 mln
NET PROFIT
+€78.3 mln
NET FINANCIAL POSITION
€25.6 mln
FREE CASH FLOW
+103 units
LIAISON/LIAISON XL INSTALLED
2018
FY
Growth in revenues, profitability and net profit in 2018
Saluggia (Italy), March 14, 2019 – The Board of Directors of DiaSorin S.p.A. (FTSE MIB: DIA), global leader in the research, production and marketing of diagnostic tests, meeting today: examined and approved the Group’s Consolidated Financial Statements at December 31, 2018, examined and approved the Company’s Draft Statutory Financial Statements at December 31, 2018.
Highlights
€669.2 mln
REVENUES
€255.4 mln
EBITDA
€ 158.1 mln
NET PROFIT
+€75.3 mln
NET FINANCIAL POSITION
€163.6 mln
FREE CASH FLOW
+451 units
LIAISON/LIAISON XL INSTALLED
9M
Growth in revenues and net profit in the first nine months of 2018 for the DiaSorin Group
Saluggia (Italy), November 7, 2018 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, met today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, and examined and approved the consolidated economic and financial results of the first 9 months of 2018.
Highlights
€494.0 mln
REVENUES
€187.1 mln
EBITDA
€116.8 mln
NET PROFIT
+€128.8 mln
NET FINANCIAL POSITION
€100.6 mln
FREE CASH FLOW
+336 unità
LIAISON/LIAISON XL INSTALLED
H1
Strong increase in net profit and free cash flow
Saluggia (Italy), August 2, 2018 – The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, met today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, and examined and approved the consolidated economic and financial results of H1’18.
Highlights
€331.2 mln
REVENUES
€128.2 mln
EBITDA
€80.9 mln
NET PROFIT
+€103.7 mln
NET FINANCIAL POSITION
€69,2 mln
FREE CASH FLOW
+225 unità
LIAISON/LIAISON XL INSTALLED
Q1
Growth in revenues and profitability in the first quarter 2018
Saluggia (Italy), May 8, 2018 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, met today in Saluggia under the Chairmanship of Mr. Gustavo Denegri, and examined and approved the consolidated economic and financial results of Q1’18.
Highlights
€164.5 mln
REVENUES
€63.3 mln
EBITDA
€50.7 mln
EBIT
€38.3 mln
NET PROFIT
+€168.6 mln
NET FINANCIAL POSITION
€27.8 mln
FREE CASH FLOW
2017
FY
Growth in revenues, profitability and net profit in 2017
Saluggia (Italy), March 7, 2018 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA) examined and approved the Group’s Consolidated Financial Statements at December 31, 2017.
Proposed ordinary dividend of € 0.85 per share and special dividend of € 1.80 per share. Revenues and EBITDA guidance achieved.
Highlights
€637.5 mln
REVENUES
€237.9 mln
EBITDA
€184.4 mln
EBIT
€139.9 mln
NET PROFIT
+€149.3 mln
NET FINANCIAL POSITION
€132.1 mln
FREE CASH FLOW
+536
LIAISON/LIAISON XL INSTALLED
2016
FY
DiaSorin: Net Profit and Cash Generation reached record highs in 2016, driven by growth in Revenues and Profitability
Saluggia (Italy), March 8, 2017 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, meeting today examined and approved the Group’s Consolidated Financial Statements at December 31, 2016
Highlights
€659.3 mln
REVENUES
€217.3 mln
EBITDA
€172.6 mln
EBIT
€112.6 mln
NET PROFIT
€71.2 mln
NET FINANCIAL POSITION
€132.2 mln
FREE CASH FLOW
+526 units
LIAISON/LIAISON XL INSTALLED
2015
FY
Net profit and cash generation reached record highs
Saluggia (Italy), March 9, 2016 - The Board of Directors of DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA), a global leader in the production of diagnostic tests, meeting today, examined and approved the Group’s Consolidated Financial Statements at December 31, 2015 and proposed the distribution of a dividend of 35,748,899.55 euros, equal to € 0.65 on each share outstanding.
Highlights
€499.2 mln
REVENUES
€185.0 mln
EBITDA
€152.0 mln
EBIT
€100.5 mln
NET PROFIT
+€267.9 mln
NET FINANCIAL POSITION
€108.2 mln
FREE CASH FLOW
+464
LIAISON/LIAISON XL INSTALLED
2014
FY
The Board of Directors of DiaSorin S.p.A. approves the full year 2014 results reporting strong cash flow and solid net financial position following the growth in revenues and profit
Saluggia, March 3, 2015 - The Board of Directors of DiaSorin S.p.A approved the Group’s Consolidated Financial Statements at December 31, 2014 and the distribution of a dividend of 32,929,954.20 euros, equal to € 0.60 on each share outstanding.
Highlights (mln/€)
443.8
REVENUES
160.3
EBITDA
129.9
EBIT
84.1
NET PROFIT
166.3
NET FINANCIAL POSITION
91.3
FREE CASH FLOW
+600
LIAISON/LIAISON XL INSTALLED